$SILK
Silk Road Medical Inc

2021 Q2 Form 10-Q Financial Statement

#000139770221000035 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $26.46M $22.05M $18.93M
YoY Change 75.27% 16.48% 48.31%
Cost Of Revenue $6.598M $5.538M $5.250M
YoY Change 23.65% 5.49% 57.23%
Gross Profit $19.86M $16.52M $13.68M
YoY Change 103.5% 20.7% 45.15%
Gross Profit Margin 75.06% 74.89% 72.27%
Selling, General & Admin $22.55M $21.19M $19.69M
YoY Change 43.1% 7.63% 42.02%
% of Gross Profit 113.55% 128.33% 143.92%
Research & Development $7.261M $5.484M $3.131M
YoY Change 114.0% 75.15% 15.66%
% of Gross Profit 36.56% 33.21% 22.88%
Depreciation & Amortization $242.0K $240.0K $184.0K
YoY Change 27.37% 30.43% 5.75%
% of Gross Profit 1.22% 1.45% 1.34%
Operating Expenses $29.81M $26.68M $22.82M
YoY Change 55.66% 16.89% 37.71%
Operating Profit -$9.952M -$10.16M -$9.140M
YoY Change 5.95% 11.19% 27.9%
Interest Expense $628.0K $623.0K $1.202M
YoY Change -47.8% -48.17% -11.09%
% of Operating Profit
Other Income/Expense, Net -$6.000K -$3.000K -$3.000K
YoY Change -89.29% 0.0% -99.98%
Pretax Income -$10.54M -$10.69M -$9.940M
YoY Change 1.83% 7.55% -58.86%
Income Tax
% Of Pretax Income
Net Earnings -$10.54M -$10.69M -$9.941M
YoY Change 1.8% 7.57% -58.85%
Net Earnings / Revenue -39.84% -48.49% -52.51%
Basic Earnings Per Share
Diluted Earnings Per Share -$305.2K -$311.3K -$317.2K
COMMON SHARES
Basic Shares Outstanding 34.48M 34.37M shares 31.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $128.1M $136.1M $97.60M
YoY Change -18.85% 39.45% 529.68%
Cash & Equivalents $101.8M $94.58M $27.55M
Short-Term Investments $26.29M $41.50M $70.10M
Other Short-Term Assets $5.877M $4.800M $1.900M
YoY Change 50.69% 152.63% 35.71%
Inventory $12.77M $11.96M $12.10M
Prepaid Expenses
Receivables $11.75M $11.11M $8.670M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $158.5M $163.9M $120.3M
YoY Change -12.46% 36.26% 314.03%
LONG-TERM ASSETS
Property, Plant & Equipment $3.428M $2.777M $2.707M
YoY Change 18.82% 2.59% -4.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $5.931M $2.680M $3.444M
YoY Change 83.45% -22.18% -13.51%
Total Long-Term Assets $9.669M $5.767M $6.461M
YoY Change 50.42% -10.74% -32.81%
TOTAL ASSETS
Total Short-Term Assets $158.5M $163.9M $120.3M
Total Long-Term Assets $9.669M $5.767M $6.461M
Total Assets $168.2M $169.7M $126.7M
YoY Change -10.3% 33.86% 227.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.958M $2.923M $3.194M
YoY Change -22.97% -8.48% 1.91%
Accrued Expenses $14.71M $13.29M $11.13M
YoY Change 60.85% 19.47% 1443.0%
Deferred Revenue $478.0K $536.0K $174.0K
YoY Change 42.69% 208.05%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.66M $16.21M $14.32M
YoY Change 42.61% 13.23% 32.68%
LONG-TERM LIABILITIES
Long-Term Debt $48.61M $48.57M $44.97M
YoY Change 7.87% 8.01% 0.84%
Other Long-Term Liabilities $6.791M $3.720M $3.497M
YoY Change 83.89% 6.38% -21.75%
Total Long-Term Liabilities $55.41M $52.29M $48.47M
YoY Change 13.63% 7.89% -1.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.66M $16.21M $14.32M
Total Long-Term Liabilities $55.41M $52.29M $48.47M
Total Liabilities $72.07M $68.51M $62.79M
YoY Change 19.23% 9.11% -31.36%
SHAREHOLDERS EQUITY
Retained Earnings -$260.1M -$249.6M -$201.5M
YoY Change 22.8% 23.88% 23.4%
Common Stock $35.00K $34.00K $31.00K
YoY Change 2.94% 9.68% 3000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $96.14M $101.2M $63.96M
YoY Change
Total Liabilities & Shareholders Equity $168.2M $169.7M $126.7M
YoY Change -10.3% 33.86% 227.78%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$10.54M -$10.69M -$9.941M
YoY Change 1.8% 7.57% -58.85%
Depreciation, Depletion And Amortization $242.0K $240.0K $184.0K
YoY Change 27.37% 30.43% 5.75%
Cash From Operating Activities -$9.038M -$11.97M -$11.80M
YoY Change -21.95% 1.5% 36.83%
INVESTING ACTIVITIES
Capital Expenditures -$804.0K $67.00K $134.0K
YoY Change 129.71% -50.0% 14.53%
Acquisitions
YoY Change
Other Investing Activities $15.00M $36.30M $30.00K
YoY Change -203.73% 120900.0%
Cash From Investing Activities $14.20M $36.23M -$108.0K
YoY Change -195.92% -33649.07% -7.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $848.0K $274.0K
YoY Change 209.49% -26.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.115M 848.0K 274.0K
YoY Change -97.07% 209.49% -136.83%
NET CHANGE
Cash From Operating Activities -9.038M -11.97M -11.80M
Cash From Investing Activities 14.20M 36.23M -108.0K
Cash From Financing Activities 2.115M 848.0K 274.0K
Net Change In Cash 7.273M 25.11M -11.63M
YoY Change -84.15% -315.92% 22.66%
FREE CASH FLOW
Cash From Operating Activities -$9.038M -$11.97M -$11.80M
Capital Expenditures -$804.0K $67.00K $134.0K
Free Cash Flow -$8.234M -$12.04M -$11.93M
YoY Change -26.68% 0.92% 36.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38847
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
SILK ROAD MEDICAL, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001397702
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8777622
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
CY2021Q1 dei City Area Code
CityAreaCode
408
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
720-9002
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
CY2021Q1 dei City Area Code
CityAreaCode
408
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
720-9002
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2021Q1 dei Trading Symbol
TradingSymbol
SILK
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34482310
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94575000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69466000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
41497000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
78016000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11106000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9070000
CY2021Q1 us-gaap Inventory Net
InventoryNet
11960000
CY2020Q4 us-gaap Inventory Net
InventoryNet
9989000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4757000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6787000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
163895000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
173328000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2777000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2844000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2680000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2832000
CY2021Q1 us-gaap Assets
Assets
169662000
CY2020Q4 us-gaap Assets
Assets
179314000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2923000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2598000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13291000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16957000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16214000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19555000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48574000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48533000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3720000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3726000
CY2021Q1 us-gaap Liabilities
Liabilities
68508000
CY2020Q4 us-gaap Liabilities
Liabilities
71814000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
179314000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22053000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34438290
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34438290
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34249649
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34249649
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
34000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
350699000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
346318000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
39000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-249585000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238891000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
101154000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
107500000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169662000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18933000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5538000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5250000
CY2021Q1 us-gaap Gross Profit
GrossProfit
16515000
CY2020Q1 us-gaap Gross Profit
GrossProfit
13683000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3131000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21194000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19692000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
26678000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
22823000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10163000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9140000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
95000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
404000
CY2021Q1 us-gaap Interest Expense
InterestExpense
623000
CY2020Q1 us-gaap Interest Expense
InterestExpense
1202000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10694000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9941000
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-33000
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
440000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-33000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
440000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10727000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9501000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34336433
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31338310
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107500000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
848000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3533000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10694000
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-33000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
101154000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71891000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
274000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1293000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-9941000
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
440000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
63957000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10694000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-9941000
CY2021Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
239000
CY2020Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
184000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3533000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1293000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-186000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-79000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
41000
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
158000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
146000
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
83000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-9000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
24000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
92000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2036000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
60000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1790000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1871000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-583000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-983000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-55000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
218000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1274000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2423000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3912000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5000
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-203000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11972000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11795000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
134000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1974000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
36300000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
2000000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36233000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
848000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
274000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
848000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
274000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25109000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11629000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69776000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39491000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94885000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27862000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
582000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
1108000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
106000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6808154
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
39.00
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Due to the coronavirus (“COVID-19”) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of March 31, 2021. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span>
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk, and Other Risks and Uncertainties</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company’s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company’s revenue while the pandemic continues.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three months ended March 31, 2021 and 2020.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company’s accounts receivable are due from a variety of health care organizations in the United States. At March 31, 2021 and December 31, 2020, no customer represented 10% or more of the Company’s accounts receivable. For the three months ended March 31, 2021 and 2020, there were no customers that represented 10% or more of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis, a Cardinal Health Company. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">currently approved portfolio. If clearance for the products in the current portfolio </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">were withdrawn by the FDA, this would have a material adverse impact on the Company.</span>
CY2021Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
227000
CY2020Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
71000
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10694000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9941000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34336433
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31338310
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4539973
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4880866
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q1 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P136D
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
7845000
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
15497000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
2208000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1785000
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10369000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10599000
CY2021Q1 us-gaap Inventory Gross
InventoryGross
12577000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
12384000
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
617000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2395000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
518000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14679000
CY2021Q1 us-gaap Inventory Net
InventoryNet
11960000
CY2020Q4 us-gaap Inventory Net
InventoryNet
9989000
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8118000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
9573000
CY2021Q1 silk Provisions For Sales Returns
ProvisionsForSalesReturns
639000
CY2020Q4 silk Provisions For Sales Returns
ProvisionsForSalesReturns
820000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1144000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2520000
CY2021Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
541000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1696000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
872000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
850000
CY2021Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
571000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
536000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
206000
CY2021Q1 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
357000
CY2020Q4 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
237000
CY2021Q1 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
119000
CY2020Q4 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
113000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
394000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
424000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13291000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16957000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1778000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20845000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
17370000
CY2021Q1 silk Long Term Debt Gross Before Accretion Of Closing Fees
LongTermDebtGrossBeforeAccretionOfClosingFees
54672000
CY2021Q1 silk Long Term Debt Unpaid Interest
LongTermDebtUnpaidInterest
5672000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
426000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
217000
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
48574000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
217000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
203000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
184000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M29D
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2640000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2798000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
872000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
850000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2625000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2850000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3497000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3700000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
804000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1096000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1127000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
904000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3930000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
434000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3497000
CY2021Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
4672000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
100525000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4288835
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
19.01
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
139668000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34438290
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34438290
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4237828
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.56
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M17D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
197407000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
235863
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
55.79
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
163151
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.20
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
21705
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
44.34
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4288835
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.01
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M2D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
139668000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2451466
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.71
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M19D
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
434000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3533000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1293000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
23548000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y21D
CY2021Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90
CY2021Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2021Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
366000
CY2020Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
293000

Files In Submission

Name View Source Status
0001397702-21-000035-index-headers.html Edgar Link pending
0001397702-21-000035-index.html Edgar Link pending
0001397702-21-000035.txt Edgar Link pending
0001397702-21-000035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
silk-20210331.xsd Edgar Link pending
silk-20210331x10q.htm Edgar Link pending
silk-20210331x10q_htm.xml Edgar Link completed
silk-20210331xex10_22.htm Edgar Link pending
silk-20210331xex31_1.htm Edgar Link pending
silk-20210331xex31_2.htm Edgar Link pending
silk-20210331xex32_1.htm Edgar Link pending
silk-20210331_cal.xml Edgar Link unprocessable
silk-20210331_def.xml Edgar Link unprocessable
silk-20210331_lab.xml Edgar Link unprocessable
silk-20210331_pre.xml Edgar Link unprocessable